Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-Arm, Single-Center, Open-Label Pilot Study of IL-2 Programmed or IL-7/IL-15 Programmed Anti-CD19:TCRz:CD28 T-cells in Patient With CD19-Positive Lymphoma That is Resistant or Refractory to Chemotherapy

NCT02652910 is registered in ClinicalTrials.gov with Xinqiao Hospital of Chongqing as lead sponsor.

NCT NCT02652910
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02652910 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-Arm, Single-Center, Open-Label Pilot Study of IL-2 Programmed or IL-7/IL-15 Programmed Anti-CD19:TCRz:CD28 T-cells in Patient With CD19-Positive Lymphoma That is Resistant or Refractory to Chemotherapy
Lead sponsor
Xinqiao Hospital of Chongqing
Phase
Phase 1/2
Overall status
Unknown status
Start date
December 31, 2015
Completion date
December 31, 2019
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent adult diffuse large cell lymphoma, recurrent follicular lymphoma, recurrent mantle cell lymphoma, stage iii adult diffuse large cell lymphoma, stage iii follicular lymphoma, stage iii mantle cell lymphoma, stage iv adult diffuse large cell lymphoma, stage iv follicular lymphoma, stage iv mantle cell lymphoma